Proactive Investors - Run By Investors For Investors

Vectura looking for new chief executive officer, with current incumbent, James Ward-Lilley to step down on 30 June

The FTSE All-Share-listed firm said Paul Fry, its chief financial officer, will assume the role of CEO in an interim capacity, in addition to his current responsibilities
Be A Boss sign
Vectura added that the search for a CEO successor will begin immediately

Vectura Group PLC (LON:VEC) is looking for a new chief executive officer (CEO) after the drugs firm revealed current incumbent, James Ward-Lilley will be stepping down from the position on 30 June 2019.

The FTSE All-Share-listed firm said Paul Fry, its chief financial officer, will assume the role of CEO in an interim capacity, in addition to his current responsibilities.

It added that the search for a CEO successor will begin immediately.

READ: Vectura surges as it wins US$90mln patent battle with GlaxoSmithKline

Bruno Angelici, Vectura’s chairman commented: “Following the successful merger with Skyepharma in 2016, James has demonstrated great resilience building an effective and robust business.

“This has been reflected in strong 2018 financial and operational performance, followed by positive news flow this year. During his time he has also built a culture of effective employee engagement and a significantly strengthened and talented team.”

The chairman added: “The Board and James have agreed that after four years as CEO it is now time for a new leader to take Vectura through its next phase of development. We look forward, in due course, to announcing the appointment of a new CEO."

In a note to clients, analysts at Peel Hunt commented: “The growth outlook and long-term strategy, which has pivoted several times since James Ward-Lilley’s appointment in 2015, have been a focus and source of concern for some investors for some time. Today’s announcement is thus not entirely surprising.”

They added: “We remain Hold and retain our 119p target price pending further clarity on the medium to long-term strategy.”

In morning trading, shares in Vectura were 1.5% higher at 80.20p.

 -- Adds analyst comment, updates share price --

View full VEC profile View Profile

Vectura Group PLC Timeline

Related Articles

blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use